Posted by Michael Wonder on 29 Jun 2020
Health economic assessment of Ondexxya in life-threatening or uncontrolled bleeding
26 June 2020 - TLV has developed a health economic assessment for the regions of the drug Ondexxya (andexanet alfa).
Ondexxya is intended for adult patients treated with a direct factor Xa inhibitor Eliquis (apixaban) or Xarelto (rivaroxaban) where the drug's thinning effect must be abolished due to life-threatening or uncontrolled bleeding.
TLV estimates that the cost per quality adjusted life year is between SEK 400,000 and 1.6 million for intracranial haemorrhage and, due to very high uncertainties, TLV has reported sensitivity analyses and not a cost per quality adjusted life year for severe gastro-intestinal bleeding.
